Final titer = 4.2 g/L, viability >75% at harvest. A 2.5-fold improvement over initial process.

Transitioning the process from a 2 L benchtop scale to a 2,000 L pilot scale introduces complex engineering challenges, primarily related to mass transfer and mixing. Scale-Up Challenges

Methotrexate (MTX) amplification was used to select high-producing clones.

The step achieved a turbidity reduction to < 10 NTU and a step yield of 92%, protecting the downstream Protein A column from fouling. 3. Downstream Processing: Purification and Safety Assurance

It outlines a systematic approach to identifying which product attributes (like glycosylation or aggregation) significantly impact safety and efficacy. Upstream Manufacturing Development:

| Step | Resin | Mode | Yield | Purity (monomer) | HCP (ppm) | |------|-------|------|-------|------------------|------------| | CEX | SP Sepharose FF | Bind-elute | 85% | 99.2% | 15 | | AEX | Q Sepharose FF | Flow-through | 92% (no binding) | 98.5% | 8 |

Protein A capacity remains stable at 40 g/L resin. Elution at pH 3.5 yields 95% purity with <0.1% aggregates. However, the low-pH elution creates a new problem: inactivation of a small fraction of Mab-X, reducing potency by 10%.

Continuous processing offers transformative benefits. By linking upstream perfusion bioreactors directly to downstream multi-column chromatography (MCC), the entire manufacturing process runs uninterrupted. This leads to a more homogeneous product, significantly reduced equipment footprint (70% smaller, by some estimates), and dramatic cost reductions. Continuous processing can achieve up to 35% cost savings compared to batch methods for annual productions of 100–500 kg. Companies like Enzene, with their FCCM™ platform, have already achieved mAb production costs of less than $40 per gram, a fraction of the $150-300 per gram typical of fed-batch processes.